Budget vs. Premium: Both Non-Cross-Linked
Hyalgan and Monovisc share one important characteristic: neither is cross-linked. They both use natural, unmodified hyaluronic acid. But that is where the similarities end. Hyalgan is the budget leader requiring 5 visits. Monovisc is a premium single-shot with 3-4x the molecular weight.
Quick Comparison Table
| Feature | Hyalgan | Monovisc |
|---|---|---|
| Manufacturer | Fidia Farmaceutici | Anika Therapeutics |
| Injections needed | 5 weekly (or 3) | 1 |
| Volume per injection | 2 mL | 4 mL |
| Total volume | 10 mL (5-shot) | 4 mL |
| Molecular weight | 500-730 kDa | 1-2.9 million Da |
| Cross-linked | No | No |
| Source | Avian | Avian |
| Bird allergy safe | No | No |
| FDA approval | 1997 | 2014 |
| HCPCS Code | J7321 | J7327 |
| Duration | Up to 6 months | Up to 6 months |
| Self-pay cost | $400-$800 | $800-$1,200 |
What Makes Hyalgan the Budget Leader?
Hyalgan’s position as the most affordable HA product comes from several factors:
- Oldest product on the market - FDA-approved in 1997, long past any patent protection premiums
- Low molecular weight - Less expensive to manufacture and purify
- Established supply chain - Nearly 30 years of production efficiency
- Competition-driven pricing - Must compete against newer, more convenient options
Hyalgan by the Numbers
- Cost per mL (self-pay): ~$40-$80
- Total drug cost: $400-$800
- Office visits: 5 (sometimes 3)
- Copays (Medicare): 5 x $25-$50 = $125-$250
- Total with Medicare: $175-$400
Why Doctors Still Choose It
Some physicians prefer Hyalgan because:
- It has the most extensive long-term safety data of any HA product
- Low molecular weight HA may have unique anti-inflammatory properties
- The 5-visit protocol allows careful monitoring of patient response
- Lower drug cost benefits patients paying out of pocket
What Makes Monovisc Premium?
Monovisc represents the other end of the HA spectrum: high molecular weight, non-cross-linked, single injection.
Monovisc by the Numbers
- Cost per mL (self-pay): ~$200-$300
- Total drug cost: $800-$1,200
- Office visits: 1
- Copays (Medicare): 1 x $25-$50 = $25-$50
- Total with Medicare: $100-$200
Why Doctors Choose It
- Convenience of single injection for time-pressed patients
- High molecular weight without the risks of cross-linking
- Same manufacturer as Orthovisc with proven track record
- Preferred by providers who value non-cross-linked formulations
The Molecular Weight Gap
This comparison has the largest molecular weight gap of any brand-vs-brand HA comparison:
Hyalgan: 500-730 kDa (low) Monovisc: 1-2.9 million Da (high)
That is a 2-5x difference in molecular weight.
What does this mean clinically? Lower MW HA (Hyalgan) may penetrate cartilage tissue more effectively. Higher MW HA (Monovisc) provides more viscosity and cushioning. Both approaches have clinical evidence supporting their effectiveness.
The research does not clearly favor one molecular weight over the other for overall pain relief outcomes.
True Cost Comparison
When you compare total out-of-pocket costs including office visits, the gap narrows:
| Scenario | Hyalgan (5-shot) | Monovisc |
|---|---|---|
| Self-pay, no insurance | $525-$1,050 | $825-$1,250 |
| Medicare | $175-$400 | $100-$200 |
| Private insurance | $150-$350 | $100-$250 |
Surprise finding: With insurance, Monovisc often costs less than Hyalgan because the single-visit savings on copays outweighs the higher drug cost. The cost advantage of Hyalgan mainly applies to self-pay patients.
Making Your Decision
Choose Hyalgan if:
- You are paying self-pay and want the lowest drug cost
- You value the longest safety track record (since 1997)
- Your doctor specifically recommends low MW HA
- You do not mind 5 weekly appointments
- You want the maximum total HA volume (10 mL)
Choose Monovisc if:
- You want single-visit convenience
- You prefer high molecular weight non-cross-linked HA
- You have insurance (the copay savings often offset the higher drug cost)
- Scheduling multiple visits is difficult
- You like Anika Therapeutics products (same maker as Orthovisc)
Frequently Asked Questions
Is Hyalgan less effective because it is cheaper?
No. Price does not determine effectiveness. Hyalgan has decades of clinical data supporting its efficacy. It is cheaper primarily because it has been on the market longest and uses lower molecular weight HA that costs less to produce.
Can I start with Hyalgan and switch to Monovisc later?
Yes. Many patients try Hyalgan first and later switch to Monovisc for convenience if they respond well to HA treatment.
Which is better for severe arthritis?
Neither HA product works consistently well for Stage 4 bone-on-bone arthritis. Both are most effective for mild-to-moderate OA (Stages 2-3).
Does Monovisc last longer than Hyalgan?
Both are reported to last up to 6 months. Individual results vary regardless of which product you choose.
The Bottom Line
Hyalgan and Monovisc are both non-cross-linked, avian-derived HA products at opposite ends of the convenience and cost spectrum.
- Hyalgan wins on upfront drug cost and offers the longest safety record in the industry
- Monovisc wins on convenience and often costs less with insurance due to single-visit copay savings
Both provide comparable clinical outcomes for knee osteoarthritis. Your choice should be driven by cost considerations, scheduling needs, and your doctor’s recommendation.
Find HA Injection Providers
Connect with specialists offering both budget and premium viscosupplementation options.
Your information is secure. See our Privacy Policy and Terms of Service.
Thank You!
We've received your request. A provider specialist will contact you within 1-2 business days to help you find the right care.
What happens next?
- 1 We'll verify your insurance coverage
- 2 Match you with quality providers in your area
- 3 Contact you to discuss your options
Questions? Browse our guides:
How to Choose a ProviderRelated Comparisons
HA Treatment Comparisons
Get evidence-based comparisons of viscosupplementation products.
Join 10,000+ readers. No spam.